Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis.

Publication Type:

Journal Article


Journal of the National Cancer Institute, Volume 105, Issue 21, p.1600-7 (2013)


2013, October 2013, Public Health Sciences Division


In investigations of the effectiveness of surgery and adjuvant chemotherapy for gastric cancers, overall survival (OS) is considered the gold standard endpoint. However, the disadvantage of using OS as the endpoint is that it requires an extended follow-up period. We sought to investigate whether disease-free survival (DFS) is a valid surrogate for OS in trials of adjuvant chemotherapy for gastric cancer.